The Series A round was led by existing investor Khosla Ventures with participation from new investors including Data Collective (DCVC), Greenbox Venture Partners, Minneapolis Heart Institute Ventures and Georges Harik. Proceeds will be used to continue clinical validation, accelerate technological development and bring Bay Labs' products to the U.S. market. In addition, Ben Ling, general partner at Khosla Ventures, and Armen Vidian, operating partner at DCVC, will join Bay Labs' Board of Directors.

Physicians today need imaging studies that provide high-quality diagnostic capabilities no matter where the patient is, from the inpatient hospital setting to the outpatient and point of care settings. Bay Labs applies AI to cardiovascular imaging to help in the diagnosis and management of heart disease. An echocardiographic exam (ultrasound images of the heart) is the gateway to cardiovascular disease diagnosis and a key to disease management and appropriate timing of intervention. The company's deep learning technology, a type of AI algorithm, is designed to help medical professionals of all skill levels perform and interpret echocardiograms and may improve the treatment of heart diseases. Bay Labs has partnered with the Minneapolis Heart Institute and Allina Health, Northwestern Medicine, Duke University School of Medicine, and cardiologists at Stanford University to develop, test and validate deep learning algorithms for echocardiography.

"We're gratified by the continued support from our existing investor Khosla Ventures and we welcome our new investors - all of whom share our vision about how deep learning technology can address two key problems in diagnostic cardiology: acquisition and interpretation of echocardiograms," said Charles Cadieu, co-founder and CEO of Bay Labs. "We welcome Ben Ling and Armen Vidian as board members and look forward to their strategic contributions to our efforts to enable providers in achieving high-quality cardiac imaging results to improve patient care."

"Bay Labs' unique application of AI with ultrasound has the potential to enable medical professionals to provide faster and better care to patients," said Ben Ling, general partner at Khosla Ventures. "We are excited to increase our investment in Bay Labs to revolutionize ultrasound."

"We are impressed with the strength of the Bay Labs AI engine to bring consistently high-quality ultrasound images and key data to physicians when they need it most - at the point of care, and we are especially excited to see such early enthusiasm from some of the world's leading physicians," said Armen Vidian, operating partner at DCVC. "We see tremendous potential for this intelligent, data-rich technology to impact how and when physicians direct patient care to dramatically improve outcomes."

About Bay Labs

Bay Labs is a San Francisco-based privately held company focused on increasing quality, value and access to medical imaging by combining deep learning and ultrasound. Founded in 2013, Bay Labs applies artificial intelligence to cardiovascular imaging, and its deep learning technology is being designed to help medical professionals of all skill levels perform and interpret high-quality echocardiography to ultimately benefit their patients. Bay Labs products are for investigational use only and currently are not for sale. For more information about Bay Labs, visit www.baylabs.io/.